ProKidney Corp.

Equities

PROK

KYG7S53R1049

Biotechnology & Medical Research

End-of-day quote Nasdaq 06:00:00 2024-06-17 pm EDT 5-day change 1st Jan Change
2.68 USD -8.22% Intraday chart for ProKidney Corp. -1.83% +50.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ProKidney Closes Public, Registered Direct Offerings MT
ProKidney Prices Upsized $130 Million Stock Offering MT
Top Midday Decliners MT
Wall Street Set to Open Lower Tuesday as Investors Await Fed Decision, Inflation Data MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
Top Premarket Decliners MT
ProKidney Launches $125 Million Stock Offering; Shares Fall After-Hours MT
Sector Update: Health Care Stocks Decline Premarket Monday MT
ProKidney Corp. Announces Positive Interim Regen-007 Phase 2 Trial Data and Provides Clinical and Operational Updates CI
Transcript : ProKidney Corp. - Special Call
ProKidney Reports 'Positive Interim Results' for Potential Chronic Kidney Disease Treatment MT
Transcript : ProKidney Corp. - Special Call
ProKidney Q1 Loss Unchanged From Year Earlier MT
ProKidney Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations CI
ProKidney Posts Wider 2023 Loss MT
ProKidney Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BofA Securities Downgrades ProKidney to Neutral From Buy, Cuts Price Target to $2 From $8 MT
ProKidney Corp. Announces Termination of Deepak Jain as Chief Operating Officer CI
Prokidney Appoints Nikhil Pereira-Kamath as Chief Business Officer CI
ProKidney Files $500 Million Mixed Shelf MT
Prokidney Insider Sold Shares Worth $9,498,584, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Advance in Late Afternoon Trading MT
Sector Update: Health Care MT
Top MIdday Gainers MT
Chart ProKidney Corp.
More charts
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.5 USD
Average target price
4.833 USD
Spread / Average Target
+93.33%
Consensus
  1. Stock Market
  2. Equities
  3. PROK Stock
  4. News ProKidney Corp.
  5. ProKidney Q1 Loss Unchanged From Year Earlier